Low-dose LPS and calorie restriction combined therapy for pancreatic ductal adenocarcinoma: an in vitro and in vivo study

Bahar Beydogan; Başak Işıldar; Zeynep Mine Coşkun Yazıcı; Meral Koyutürk; Sema Bolkent

Makale detayları

Low-dose LPS and calorie restriction combined therapy for pancreatic ductal adenocarcinoma: an in vitro and in vivo study

Yazarlar:

Bahar Beydogan | Başak Işıldar | Zeynep Mine Coşkun Yazıcı | Meral Koyutürk | Sema Bolkent

Yayıncı:

Marmara University

Ana Başlıklar:

Surgery (Other)

Dergi:

Marmara Medical Journal Vol.38 Issue 1, pp.15-23

Belge Tipi:

Makale

Yayın Tarihi:

1/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001339937

pISSN:

1019-1941

Anahtar kelimeler:

Özet:

 Objective: This study aimed to evaluate the therapeutic effects of lipopolysaccharide LPS on Panc02 cells since LPS is an inflammatory agent with the potential to activate the immune system and reorganize the tumor microenvironment. Moreover, calorie restriction CR has been investigated in combination with LPS as a prospective adjuvant intervention for cancer therapy. Materials and Methods: Panc02 cells were cultured in two distinct media with low and high-glucose concentrations, and cell viability was investigated after applying varying doses of LPS to culture media. The in vivo effects of LPS and CR were investigated on the mice subcutaneous pancreatic ductal adenocarcinoma PDAC tumor model in terms of tumor mass, histological examination, mRNA expression profiles, and biochemical parameters. Results: The lowest cell count was detected in the cells treated with 10 μgml LPS in low-glucose environments in vivo. Tumor mass significantly decreased in the PLPSCR group in vivo. The mRNA expression analysis of tumor tissues indicated that PLPSCR acts through NF-κB, JNK, and IL-6 signaling pathways. Conclusion: Lipopolysaccharide alone is insufficient to show therapeutic effects, but it can inhibit tumor development by acting on NF-κB and JNK pathways when combined with CR. This study gives insight into developing new treatment options for PDAC.

 Objective: This study aimed to evaluate the therapeutic effects of lipopolysaccharide LPS on Panc02 cells since LPS is an inflammatory agent with the potential to activate the immune system and reorganize the tumor microenvironment. Moreover, calorie restriction CR has been investigated in combination with LPS as a prospective adjuvant intervention for cancer therapy. Materials and Methods: Panc02 cells were cultured in two distinct media with low and high-glucose concentrations, and cell viability was investigated after applying varying doses of LPS to culture media. The in vivo effects of LPS and CR were investigated on the mice subcutaneous pancreatic ductal adenocarcinoma PDAC tumor model in terms of tumor mass, histological examination, mRNA expression profiles, and biochemical parameters. Results: The lowest cell count was detected in the cells treated with 10 μgml LPS in low-glucose environments in vivo. Tumor mass significantly decreased in the PLPSCR group in vivo. The mRNA expression analysis of tumor tissues indicated that PLPSCR acts through NF-κB, JNK, and IL-6 signaling pathways. Conclusion: Lipopolysaccharide alone is insufficient to show therapeutic effects, but it can inhibit tumor development by acting on NF-κB and JNK pathways when combined with CR. This study gives insight into developing new treatment options for PDAC.

 Objective: This study aimed to evaluate the therapeutic effects of lipopolysaccharide LPS on Panc02 cells since LPS is an inflammatory agent with the potential to activate the immune system and reorganize the tumor microenvironment. Moreover, calorie restriction CR has been investigated in combination with LPS as a prospective adjuvant intervention for cancer therapy. Materials and Methods: Panc02 cells were cultured in two distinct media with low and high-glucose concentrations, and cell viability was investigated after applying varying doses of LPS to culture media. The in vivo effects of LPS and CR were investigated on the mice subcutaneous pancreatic ductal adenocarcinoma PDAC tumor model in terms of tumor mass, histological examination, mRNA expression profiles, and biochemical parameters. Results: The lowest cell count was detected in the cells treated with 10 μgml LPS in low-glucose environments in vivo. Tumor mass significantly decreased in the PLPSCR group in vivo. The mRNA expression analysis of tumor tissues indicated that PLPSCR acts through NF-κB, JNK, and IL-6 signaling pathways. Conclusion: Lipopolysaccharide alone is insufficient to show therapeutic effects, but it can inhibit tumor development by acting on NF-κB and JNK pathways when combined with CR. This study gives insight into developing new treatment options for PDAC.

 Objective: This study aimed to evaluate the therapeutic effects of lipopolysaccharide LPS on Panc02 cells since LPS is an inflammatory agent with the potential to activate the immune system and reorganize the tumor microenvironment. Moreover, calorie restriction CR has been investigated in combination with LPS as a prospective adjuvant intervention for cancer therapy. Materials and Methods: Panc02 cells were cultured in two distinct media with low and high-glucose concentrations, and cell viability was investigated after applying varying doses of LPS to culture media. The in vivo effects of LPS and CR were investigated on the mice subcutaneous pancreatic ductal adenocarcinoma PDAC tumor model in terms of tumor mass, histological examination, mRNA expression profiles, and biochemical parameters. Results: The lowest cell count was detected in the cells treated with 10 μgml LPS in low-glucose environments in vivo. Tumor mass significantly decreased in the PLPSCR group in vivo. The mRNA expression analysis of tumor tissues indicated that PLPSCR acts through NF-κB, JNK, and IL-6 signaling pathways. Conclusion: Lipopolysaccharide alone is insufficient to show therapeutic effects, but it can inhibit tumor development by acting on NF-κB and JNK pathways when combined with CR. This study gives insight into developing new treatment options for PDAC.

Makale detayları

Low-dose LPS and calorie restriction combined therapy for pancreatic ductal adenocarcinoma: an in vitro and in vivo study

Yazarlar:

Bahar Beydogan | Başak Işıldar | Zeynep Mine Coşkun Yazıcı | Meral Koyutürk | Sema Bolkent

Yayıncı:

Marmara University

Ana Başlıklar:

Surgery (Other)

Dergi:

Marmara Medical Journal Vol.38 Issue 1, pp.15-23

Belge Tipi:

Makale

Yayın Tarihi:

1/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001339937

pISSN:

1019-1941

Panc02

Lipopolysaccharide

Calorie restriction

Subcutaneous pancreatic ductal adenocarcinoma model

Cancer

Sayı

Makale detayları

Low-dose LPS and calorie restriction combined therapy for pancreatic ductal adenocarcinoma: an in vitro and in vivo study

Yazarlar: Bahar Beydogan | Başak Işıldar | Zeynep Mine Coşkun Yazıcı | Meral Koyutürk | Sema Bolkent

Yayıncı: Marmara University

Ana Başlıklar: Surgery (Other)

Dergi: Marmara Medical Journal Vol.38 Issue 1, pp.15-23

Belge Tipi: Makale

Yayın Tarihi: 1/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001339937

pISSN: 1019-1941

Panc02

Lipopolysaccharide

Calorie restriction

Subcutaneous pancreatic ductal adenocarcinoma model

Cancer

Sayı

Yazarlar:

Bahar Beydogan | Başak Işıldar | Zeynep Mine Coşkun Yazıcı | Meral Koyutürk | Sema Bolkent

Yayıncı:

Marmara University

Ana Başlıklar:

Surgery (Other)

Dergi:

Marmara Medical Journal Vol.38 Issue 1, pp.15-23

Belge Tipi:

Makale

Yayın Tarihi:

1/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001339937

pISSN:

1019-1941